News
NDRA
4.960
-6.59%
-0.350
Weekly Report: what happened at NDRA last week (1208-1212)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 4d ago
Weekly Report: what happened at NDRA last week (1201-1205)?
Weekly Report · 12/08 10:29
ENDRA Life Sciences Is Maintained at Buy by Ascendiant Capital
Dow Jones · 12/08 10:25
ENDRA Life Sciences Price Target Cut to $30.00/Share From $38.00 by Ascendiant Capital
Dow Jones · 12/08 10:25
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30
Benzinga · 12/08 10:16
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/04 21:05
Endra Life Sciences announces results from Taeus Liver device feasibility study
TipRanks · 12/04 13:20
ENDRA Life Sciences Announces New Results From 2025 TAEUS Liver Device Feasibility Study Showing TAEUS' TAFF Measurement Closely Tracks MRI-PDFF Gold Standard At Critical LFF Thresholds Of 12-17% And 20-22%
Benzinga · 12/04 13:03
ENDRA Life Sciences Reports TAEUS Device Matches MRI Accuracy in Liver Disease Study
Reuters · 12/04 13:01
ENDRA’S TAEUS® LIVER MATCHES MRI-PDFF PERFORMANCE AT KEY CLINICAL THRESHOLDS, POSITIONING DEVICE FOR MASLD/MASH TRIAL USE
Reuters · 12/04 13:00
ENDRA LIFE SCIENCES INC - SECOND FEASIBILITY STUDY FOR TAEUS LIVER DEVICE BEGUN IN LONDON, ONTARIO
Reuters · 12/04 13:00
Weekly Report: what happened at NDRA last week (1124-1128)?
Weekly Report · 12/01 10:24
ENDRA Life Sciences CTO Resigns as CFO Compensation Terms Change
Reuters · 11/28 21:23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/26 12:05
Weekly Report: what happened at NDRA last week (1117-1121)?
Weekly Report · 11/24 10:29
ENDRA's Updated TAEUS Liver Device Shows MRI-Level Accuracy Across All Stages Of Steatotic Liver Disease In New Feasibility Study
Benzinga · 11/20 13:09
ENDRA Life Sciences Announces Prelim. Results From Single-Site Clinical Feasibility Study Evaluating TAEUS Liver Device For Quantifying Liver Fat Fraction
Benzinga · 11/20 13:07
ENDRA Life Sciences Reports Positive Feasibility Study Results for TAEUS Liver Fat Quantification Device
Reuters · 11/20 13:01
Endra Life Sciences GAAP EPS of -$2.10 misses by $0.15
Seeking Alpha · 11/17 13:23
More
Webull provides a variety of real-time NDRA stock news. You can receive the latest news about Endra Life Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About NDRA
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.